Home › Funds › GW&K Investment Management, LLC › NBIX
GW&K Investment Management, LLC position in NBIX
NEUROCRINE BIOSCIENCES INC · Health Care
GW&K Investment Management, LLC reported holding 557,733 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$79.1M, representing 0.67% of its reported portfolio and ranking #33 among its reported holdings. GW&K Investment Management, LLC has disclosed NBIX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How GW&K Investment Management, LLC's NBIX position evolved
GW&K Investment Management, LLC first disclosed a stake in NBIX in Q3 2023 at 554,791 shares (US$62.4M). The position peaked in Q2 2026 at 567,421 shares, worth US$95.6M. Across 13 filings, GW&K Investment Management, LLC increased the stake 4 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 557,733 shares valued at US$79.1M — a reduction of -9,688 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 554.79K | $62.41M | New |
| Q4 2023 | 535.96K | $70.62M | Reduce |
| Q1 2024 | 527.87K | $72.80M | Reduce |
| Q2 2024 | 546.07K | $75.18M | Add |
| Q3 2024 | 510.09K | $58.77M | Reduce |
| Q4 2024 | 514.08K | $70.17M | Add |
| Q1 2025 | 511.36K | $56.56M | Reduce |
| Q2 2025 | 612.37K | $76.97M | Add |
| Q3 2025 | 594.38K | $83.44M | Reduce |
| Q4 2025 | 576.65K | $81.79M | Reduce |
| Q1 2026 | 593.73K | $78.22M | Add |
| Q2 2026 | 567.42K | $95.63M | Reduce |
| Q3 2026 | 557.73K | $79.11M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NBIX and 13F data
NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 30 other funds we track also report a position in NBIX — the largest reported positions include Two Sigma Investments (US$349.9M), Renaissance Technologies (US$326.3M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NBIX
- Two Sigma Investments 2.08M sh · $349.92M · Q2 2026
- Renaissance Technologies 2.30M sh · $326.33M · Q3 2026
- Vestal Point Capital, LP 1.88M sh · $316.85M · Q2 2026
- RTW INVESTMENTS, LP 1.27M sh · $213.69M · Q2 2026
More on GW&K Investment Management, LLC
FAQ
How long has GW&K Investment Management, LLC held NBIX?
GW&K Investment Management, LLC has disclosed NBIX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is GW&K Investment Management, LLC's current position in NBIX?
As of Q3 2026, GW&K Investment Management, LLC holds 557.73K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $79.11M, representing 0.67% of its reported portfolio and ranking #33.
Has GW&K Investment Management, LLC been buying or selling NBIX?
In the latest 13F filing (Q3 2026), GW&K Investment Management, LLC reduced its position in NBIX. The position peaked in Q2 2026 at 567.42K shares.
Which other funds hold NBIX?
Other major institutional holders of NBIX include Two Sigma Investments, Renaissance Technologies, Vestal Point Capital, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.